Extract
The care of patients with idiopathic pulmonary fibrosis (IPF) has been transformed by the widespread approval of antifibrotic therapies [1]. Within primary care-based healthcare systems, the diagnosis of IPF and commencement of antifibrotic therapy typically requires a patient referral from a primary care physician to a respiratory physician in secondary care, with referral then made to a specialist interstitial lung disease (ILD) centre [2]. Following ILD centre review and multidisciplinary team (MDT) discussion, a diagnosis of IPF is made and antifibrotic therapy may be commenced.
Abstract
For patients with IPF, length of time in healthcare systems prior to review in an ILD clinic reflects disease severity and may impact upon patient outcome https://bit.ly/2TkO26r
Footnotes
Conflict of interest: C.J. Brereton reports nonfinancial support from Boehringer Ingelheim outside the submitted work.
Conflict of interest: T. Wallis has nothing to disclose.
Conflict of interest: M. Casey has nothing to disclose.
Conflict of interest: L. Fox reports nonfinancial support from Roche for a study day in Manchester and nonfinancial support from Boehinger Ingelheim to attend ILD INN, outside the submitted work.
Conflict of interest: K. Pontoppidan reports personal fees for conference attendance from Bayer outside the submitted work.
Conflict of interest: D. Laws has nothing to disclose.
Conflict of interest: J. Graves reports personal fees from GSK for an asthma talk to practice nurses and personal fees for a Pfizer-funded smoking cessation webinar, outside the submitted work.
Conflict of interest: V. Titmuss has nothing to disclose.
Conflict of interest: S. Kearney has nothing to disclose.
Conflict of interest: S. Evans has nothing to disclose.
Conflict of interest: A. Grove has nothing to disclose.
Conflict of interest: S. Hamid has nothing to disclose.
Conflict of interest: L. Richeldi reports personal fees from Biogen for consulting activity; grants and personal fees for membership of an advisory board from Roche; personal fees for consulting activity from ImmuneWorks; grants, and personal fees for membership of a steering committee and an advisory board from Boehringer Ingelheim; personal fees for consulting activity from Celgene and Nitto; personal fees for membership of advisory boards from FibroGen and Promedior; and personal fees for consulting activity from Pliant Therapeutics, Asahi Kasei, Toray, BMS, RespiVant and CSL Behring, all outside the submitted work.
Conflict of interest: K.M.A. O'Reilly reports grants and personal fees for an advisory board from Boehringer Ingelheim, and personal fees for talks and advisory work from Roche, outside the submitted work.
Conflict of interest: S.V. Fletcher reports personal fees and nonfinancial support from Boehringer Ingelheim and Roche/Intermune, outside the submitted work
Conflict of interest: M.G. Jones has nothing to disclose.
- Received March 6, 2020.
- Accepted May 13, 2020.
- Copyright ©ERS 2020
This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.